Mastodawn

piti Sep 16, 2024

Lars Fischer Sep 16, 2024

Ein deutscher Politiker, ich glaube Markus Söder, hat vor ner Weile mal folgende Beobachtung gemacht:

Wenn du als Landespolitiker Hochwasserschutz durchsetzen willst, hassen dich alle. Die Gemeinden, die Bauern...
Wenn du dagegen bei ner Überschwemmung mit Gummistiefeln und ernstem Gesicht im Katastrophengebiet auftauchst, kriegst du Titelseiten und Applaus.

Ich vermute, das ist ein wichtiger Zeil des Problems.
(Artikel kostenpflichtig)
https://www.spektrum.de/news/wie-gefaehrdet-sind-wir-bei-hitze-starkregen-und-duerre/2209979

Planlos im Kampf gegen extreme Wetterlagen

Der Klimawandel macht Hitze, Starkregen und Dürre wahrscheinlicher. Doch viele Städte und Gemeinden sind nur unzureichend auf die Unbilden des zukünftigen Wetters vorbereitet.

Spektrum.de

piti Feb 14, 2023

Wie finde ich einen Kinderarzt und einen Lungenarzt in M, die 11J ohne Präsenz der Eltern nehmen? Online ginge.

piti Jan 27, 2023

Show thread

Irene Tosetti, MD, MBA MPH Jan 27, 2023

piti Jan 27, 2023

Irene Tosetti, MD, MBA MPH Jan 27, 2023

Kids under 6 months get hospitalized as much as 50 year old with covid-19.

Solution? Get a vaccine during pregnancy

piti Jan 27, 2023

Irene Tosetti, MD, MBA MPH Jan 27, 2023

Does paxkovid help the vaccinated?
Yes.

In a study of vaccinated patients over 50 years,Paxkovid reduced risk for hospitalization (adjusted risk ratio, 0.60 [CI, 0.44 to 0.81]) and death (adjusted risk ratio, 0.29 [CI, 0.12 to 0.71]).

https://www.acpjournals.org/doi/full/10.7326/M22-2141?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System: A Population-Based Cohort Study: Annals of Internal Medicine: Vol 176, No 1

Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death among unvaccinated outpatients with early COVID-19. The clinical impact of nirmatrelvir plus ritonavir among vaccinated populations is uncertain. Objective: To assess whether nirmatrelvir plus ritonavir reduces risk for hospitalization or death among outpatients with early COVID-19 in the setting of prevalent SARS-CoV-2 immunity and immune-evasive SARS-CoV-2 lineages. Design: Population-based cohort study analyzed to emulate a clinical trial using inverse probability–weighted models to account for anticipated bias in treatment. Setting: A large health care system providing care for 1.5 million patients in Massachusetts and New Hampshire during the Omicron wave (1 January to 17 July 2022). Patients: 44 551 nonhospitalized adults (90.3% with ≥3 vaccine doses) aged 50 years or older with COVID-19 and no contraindications for nirmatrelvir plus ritonavir. Measurements: The primary outcome was a composite of hospitalization within 14 days or death within 28 days of a COVID-19 diagnosis. Results: During the study period, 12 541 (28.1%) patients were prescribed nirmatrelvir plus ritonavir, and 32 010 (71.9%) were not. Patients prescribed nirmatrelvir plus ritonavir were more likely to be older, have more comorbidities, and be vaccinated. The composite outcome of hospitalization or death occurred in 69 (0.55%) patients who were prescribed nirmatrelvir plus ritonavir and 310 (0.97%) who were not (adjusted risk ratio, 0.56 [95% CI, 0.42 to 0.75]). Recipients of nirmatrelvir plus ritonavir had lower risk for hospitalization (adjusted risk ratio, 0.60 [CI, 0.44 to 0.81]) and death (adjusted risk ratio, 0.29 [CI, 0.12 to 0.71]). Limitation: Potential residual confounding due to differential access to COVID-19 vaccines, diagnostic tests, and treatment. Conclusion: The overall risk for hospitalization or death was already low (1%) after an outpatient diagnosis of COVID-19, but nirmatrelvir plus ritonavir reduced this risk further. Primary Funding Source: National Institutes of Health.

Annals of Internal Medicine

piti Jan 12, 2023

Irene Tosetti, MD, MBA MPH Jan 12, 2023

RT @[email protected]

We must return to a world where prevention of disease is seen as better than hoping for a cure.

This is impacting hardest on all the vulnerable groups that we profess to support.

Public health must return to its role of always being a thorn in the side of disease enablers.

🐦🔗: https://twitter.com/drajm/status/1611673103427567617

Dr Miller @[email protected] on Twitter

“We must return to a world where prevention of disease is seen as better than hoping for a cure. This is impacting hardest on all the vulnerable groups that we profess to support. Public health must return to its role of always being a thorn in the side of disease enablers.”

Twitter

piti Jan 12, 2023

Irene Tosetti, MD, MBA MPH Jan 12, 2023

RT @[email protected]

Universities and colleges should provide masks, for free, to all students. And staff. Like McGill does.

The science says they work. Workplace health and safety rules says it’s important. Your equity boilerplate says your should. The expense is minimal. Just do it.

🐦🔗: https://twitter.com/jasmith_yorku/status/1612822345978109952

DrJames @YorkU (he/him/il) on Twitter

“Universities and colleges should provide masks, for free, to all students. And staff. Like McGill does. The science says they work. Workplace health and safety rules says it’s important. Your equity boilerplate says your should. The expense is minimal. Just do it.”

Twitter

piti Jan 4, 2023

Show thread

Alexander Julius Jan 4, 2023

@markus_roeder_dozent
Absolut korrekt.
Allerdings sollte man #Influenza #RSV und #SarsCoV2 meiner Meinung nach auch in Kombination betrachten:
1) Neben der Grippe sorgen auch Corona und RSV für hohe Krankenstände und eine angespannte Situation in Krankenhäusern.
2) Die Corona-Maßnahmen helfen auch, Grippe und RSV zu vermeiden. Deshalb halte ich es für fahrlässig, die Maßnahmen vor Ende der Grippewelle zu beenden.

piti Jan 4, 2023

Alexander Julius Jan 3, 2023

An alle, die sich für die sofortige Aufhebung der #CoronaMassnahmen einsetzen:
Während vergangene Grippewellen durchschnittlich einen wirtschaftlichen Schaden von 3 Mrd.€ verursacht haben, liegt der Schaden der aktuellen Grippewelle mit geschätzten 30-40 Mrd.€ bei dem zehnfachen Wert - Kosten für die medizinische Versorgung noch nicht eingerechnet.
Neben dem Abwenden von schutzbedürftigen ist die Aufhebung der #Maskenpflicht auch wirtschaftlich mal überhaupt gar keine gute Idee.
#Grippe #Corona

piti Dec 17, 2022

𝐙ｉ𝓡ᛕỮｓ 𝓫𝐈ℓㄥĮค𝔫ｉ☑️ 🇦🇹 🇮🇹Dec 16, 2022

Timothy Snyder zu derzeitigen politischen Entwicklungen in vielen Ländern.
Wir waren auch schon am Weg ...